Results 41 to 50 of about 991,798 (411)

The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. [PDF]

open access: yes, 2017
We recently found that integrin αvβ3 binds to fibroblast growth factor (FGF)-αvβ31 (FGF1), and that the integrin-binding defective FGF1 mutant (Arg-50 to glutamic acid, R50E) is defective in signalling and antagonistic to FGF1 signalling. R50E suppressed
Hamada, Yoshinosuke   +10 more
core   +2 more sources

Junctional Adhesion Molecule-C Mediates the Recruitment of Embryonic-Endothelial Progenitor Cells to the Perivascular Niche during Tumor Angiogenesis [PDF]

open access: yes, 2020
The homing of Endothelial Progenitor Cells (EPCs) to tumor angiogenic sites has been described as a multistep process, involving adhesion, migration, incorporation and sprouting, for which the underlying molecular and cellular mechanisms are yet to be ...
Bieback, Karen   +6 more
core   +1 more source

Angiogenesis in Disease

open access: yesInternational Journal of Molecular Sciences, 2022
Angiogenesis is a multi-step process by which new blood capillaries are formed starting from preexisting functional vessels [...]
La Mendola D.   +2 more
openaire   +3 more sources

Multifunctional star-shaped polylactic acid implants for use in angioplasty [PDF]

open access: yes, 2014
Star-shaped polylactic acids with different tacticity were synthesized and both polymers are capable of bestowing properties of anticoagulation and angiogenesis to their living host.
Kiran, M. S.   +3 more
core   +2 more sources

Disruption of VEGF Mediated Flk‐1 Signaling Leads to a Gradual Loss of Vessel Health and Cardiac Function During Myocardial Infarction: Potential Therapy With Pellino‐1

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background The present study demonstrates that the ubiquitin E3 ligase, Pellino‐1 (Peli1), is an important angiogenic molecule under the control of vascular endothelial growth factor (VEGF) receptor 2/Flk‐1.
Mahesh Thirunavukkarasu   +13 more
doaj   +1 more source

Tumor angiogenesis: causes, consequences, challenges and opportunities

open access: yesCellular and Molecular Life Sciences, 2019
Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same cancer tissue. These processes are orchestrated by a range of secreted
R. Lugano   +2 more
semanticscholar   +1 more source

Structural variants of biodegradable polyesterurethane in vivo evoke a cellular and angiogenic response that is dictated by architecture [PDF]

open access: yes, 2009
This is the author's accepted manuscript. The final published article is available from the link below. Copyright @ 2008 Acta Materialia Inc.The aim of this study was to investigate an in vivo tissue response to a biodegradable polyesterurethane ...
Burugapalli, K   +3 more
core   +1 more source

Prioritization and functional validation of target genes from single-cell transcriptomics studies

open access: yesCommunications Biology, 2023
Translation of academic results into clinical practice is a formidable unmet medical need. Single-cell RNA-sequencing (scRNA-seq) studies generate long descriptive ranks of markers with predicted biological function, but without functional validation, it
Liliana Sokol   +12 more
doaj   +1 more source

Angiogenesis in cancer [PDF]

open access: yesVascular Health and Risk Management, 2006
New growth in the vascular network is important since the proliferation, as well as metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and the removal of waste products. New blood and lymphatic vessels form through processes called angiogenesis and lymphangiogenesis, respectively.
Masamichi Kojiro   +4 more
openaire   +4 more sources

DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration. [PDF]

open access: yes, 2010
Deleted in liver cancer 1 (DLC1) is a RhoGTPase activation protein-containing tumor suppressor that associates with various types of cancer. Although DLC2 shares a similar domain structure with that of DLC1, the function of DLC2 is not well characterized.
Chen, N-T   +5 more
core   +3 more sources

Home - About - Disclaimer - Privacy